Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Tertiary Hospital in Northern China

Table 5

Resistance features of the CRKP and transconjugants.

Strains

Genotypes

Plasmid replicons

MIC (μg/ml)

IPM

FEP

CRO

FOX

ATM

GEN

AMK

CIP

LEV

TGC

K. pneumoniae

CRKP 3

bla KPC-2, blaSHV-11, blaTEM-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-15, blaOXA-1, acc (6′)-Ib, qepA, oqxA, and qnrB

FIB

4

>16

>32

32

>64

≤1

≤2

>4

>8

2

CRKP 4

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-9, ant(3′)-I, qepA, oqxA, and qnrS

FIB

4

>16

16

8

>64

>16

≤2

>4

4

1

CRKP 9

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-3, blaCTX-M-9, qepA, oqxA, and qnrB

FIIK FIB

256

>16

>32

>64

>64

≤1

≤2

>4

>8

2

CRKP 12

bla KPC-2, blaSHV-12, blaCTX-M-3, blaCTX-M-2, ant (3′)-I, qepA and oqxA

FIIK

8

>16

8

>64

16

≤1

≤2

0.5

1

1

CRKP 15

bla KPC-2, blaSHV-11, blaTEM-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, qepA, oqxA, and qnrB

FII

16

>16

>32

>64

>64

≤1

≤2

0.5

1

≤0.5

CRKP 17

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-3, acc (6′)-Ib, acc(3′)-IV, qepA and oqxA

FII FIIK

8

2

>32

8

>64

>16

≤2

>4

>8

2

CRKP 18

bla KPC-2, blaGES, blaSHV-33, blaCTX-M-2, blaCTX-M-9, ant (3′)-I, qepA and oqxA

FIB

32

>16

>32

>64

>64

≤1

≤2

>4

>8

2

CRKP 32

bla NDM-1, blaCTX-M-2, blaCTX-M-3, blaOXA-1, blaDHA, acc (6′)-Ib, acc (3′)-IV, ant(3′)-I qepA and qnrB

16

>16

>32

>64

≤1

>16

>64

>4

>8

4

CRKP 33

bla NDM-1, blaGES, blaCTX-M-2, blaCTX-M-3, blaOXA-1, blaDHA, acc(6′)-Ib, acc(3′)-IV, ant (3′)-I, qepA and qnrB

16

>16

>32

>64

≤1

>16

>64

>4

>8

4

CRKP 40

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-3, ant (3′)-I, qepA, and oqxA

FII FIIK

4

>16

>32

32

>64

>16

≤2

1

≤1

≤0.5

CRKP 41

bla KPC-2, blaSHV-11, blaTEM-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-15, blaOXA-1, acc (6′)-Ib, ant (3′)-IV, ant (3′)-I, qepA, and oqxA

FII FIIK

4

4

>32

>64

>64

>16

4

>4

>8

2

CRKP 47

bla KPC-2, blaSHV-11, blaTEM-1, blaCTX-M-2, blaCTX-M-3, blaOXA-1, acc (6′)-Ib qepA oqxA, and qnrB

FII FIB

4

>16

>32

>64

>64

≤1

≤2

>4

>8

4

CRKP 63

bla KPC-2, blaSHV-12, blaTEM-1, blaCTX-M-2, acc (3′)-II aac (6′)-Ib, qepA, and oqxA

FII FIIK FIB

8

>16

32

>64

>64

>16

≤2

≤0.25

≤1

1

CRKP 74

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-9 acc (3′)-IIa ant(2′)-Ia, qepA, oqxA, and qnrS

FII FIIK FIB

4

16

>32

16

>64

>16

≤2

1

≤1

1

CRKP 82

bla KPC-2, blaSHV-11, blaTEM-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-15, blaOXA-1, acc (6′)-Ib, qepA, oqxA, and qnrB

FII FIB

4

16

>32

8

>64

≤1

≤2

>4

>8

2

CRKP 85

bla KPC-2, blaSHV-12, blaCTX-M-2, blaCTX-M-3, ant (3′)-I, qepA, and oqxA

FIIK

8

4

32

32

>64

≤1

≤2

1

≤1

≤0.5

CRKP 88

bla KPC-2, blaNDM-1, blaSHV-11, blaTEM-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-15, blaOXA-1, acc (6′)-Ib, qepA, oqxA, and qnrB

FII FIB

4

>16

>32

32

>64

≤1

≤2

>4

>8

2

CRKP 89

bla KPC-2, blaNDM-1, blaIMP, blaCTX-M-1, blaCTX-M-2, blaCTX-M-3, blaCTX-M-15, ant (3′)-I, qepA, and qnrS

8

>16

>32

>64

≤1

≤1

≤2

1

≤1

≤0.5

Transconjugants

CRKP 3C

bla KPC-2, acc (6′)-Ib, and qnrB

2

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

2

CRKP 4C

bla KPC-2

4

2

4

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 9C

bla KPC-2, blaCTX-M-9, and qnrB

2

16

>32

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 12C

bla KPC-2

FIIK

4

16

4

≤8

8

≤1

≤2

≤0.5

≤1

1

CRKP 15C

bla KPC-2 and qnrB

FII

4

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 17C

bla KPC-2 and acc (6′)-Ib

FII FIIK

4

2

8

≤8

>16

≤1

≤2

≤0.5

≤1

2

CRKP 18C

bla KPC-2

2

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

2

CRKP 32C

bla NDM-1, acc (6′)-Ib and qnrB

8

>16

>32

≤8

≤1

≤1

≤2

≤0.5

≤1

4

CRKP 33C

bla NDM-1, acc (6′)-Ib, and qnrB

4

>16

>32

≤8

≤1

≤1

≤2

≤0.5

≤1

2

CRKP 40C

bla KPC-2

FII FIIK

2

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 41C

bla KPC-2, blaTEM-1blaOXA-1blaCTX-M-15 and acc (6′)-Ib

FII FIIK

4

2

>32

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 47C

bla KPC-2 acc (6′)-Ib, and qnrB

FII

8

>16

32

≤8

>16

≤1

≤2

≤0.5

≤1

4

CRKP 63C

bla KPC-2 and acc (6′)-Ib

FII

4

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 74C

bla KPC-2 and ant (2′)-Ia

FII FIIK

≤1

8

4

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 82C

bla KPC-2, acc (6′)-Ib and qnrB

FII

4

8

8

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 85C

bla KPC-2

8

2

16

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 88C

bla NDM-1, acc (6′)-Ib and qnrB

FII

≤1

>16

8

≤8

>16

≤1

≤2

≤0.5

≤1

1

CRKP 89C

bla NDM-1

8

>16

>32

≤8

≤1

≤1

≤2

1

≤1

2

IPM, imipenem; FEP, cefepime; CRO, ceftriaxone; FOX, cefoxitin; ATM, aztreonam; GEN, gentamicin; AMK, amikacin; CIP, ciprofloxacin; LEV, levofloxacin; TGC, tigecycline.